Novo Nordisk's fixed-dose combination of cagrilintide (amylin analog) + semaglutide (GLP-1 agonist) — two independent satiety pathways in a single injection. REDEFINE 1 trial: 22.7% mean body weight loss at 68 weeks. NEJM-published Phase 3 data.
CagriSema (NNC0174-0833) is a fixed-dose co-formulation developed by Novo Nordisk that combines two distinct peptide drugs into a single subcutaneous injection: cagrilintide 2.4mg (a long-acting amylin analogue) and semaglutide 2.4mg (the same GLP-1 receptor agonist used in Wegovy). The two components are co-formulated but pharmacologically independent — each molecule acts on a completely different receptor system.
Cagrilintide activates amylin receptors (AMY1 and AMY3), which are co-assembled from calcitonin receptors (CTR) and receptor activity-modifying proteins (RAMPs). Semaglutide activates GLP-1 receptors in the gut and hypothalamus. These pathways produce overlapping but mechanistically distinct satiety signals, which is the core scientific rationale: hitting two independent appetite-suppressing circuits simultaneously should produce greater and more durable weight reduction than either mechanism alone.
The REDEFINE clinical program published Phase 3 data in the New England Journal of Medicine in 2025, with REDEFINE 1 reporting 22.7% mean body weight loss at 68 weeks in adults with obesity — a result competitive with the best-in-class GLP-1/GIP dual agonists, achieved through a different receptor mechanism entirely.
📡 Weekly peptide research updates — regulatory updates, new compound profiles, COA alerts.
⚠️ FDA PCAC: -- days leftNo spam. Unsubscribe anytime. 7 peptides under review — see what's at stake →
CagriSema is the first major clinical validation of the GLP-1 + amylin combination hypothesis — demonstrating that the amylin pathway adds meaningful independent weight reduction on top of GLP-1 alone. That mechanistic finding has implications beyond CagriSema itself.
7 free research tools built around exactly this kind of compound data. No paywall, no credit card.
CagriSema operates through two pharmacologically independent receptor systems, both involved in appetite regulation and energy balance, but acting through different circuits in the brain and gut:
Semaglutide arm (GLP-1 receptor): Activates GLP-1 receptors on L-cells in the gut, beta cells in the pancreas, and neurons in the hypothalamus and brainstem. GLP-1 receptor activation suppresses glucagon, stimulates glucose-dependent insulin release, slows gastric emptying, and produces hypothalamic satiety signaling that reduces food intake. These are well-characterized mechanisms shared with the entire GLP-1 agonist drug class.
Cagrilintide arm (Amylin receptors AMY1/AMY3): Activates amylin receptors formed by calcitonin receptor (CTR) + RAMP1 (AMY1) and CTR + RAMP3 (AMY3) complexes. Amylin receptor activation suppresses glucagon secretion (independent of GLP-1's glucagon suppression), slows gastric emptying (via separate brainstem circuits from GLP-1), and generates satiety signals through the area postrema — a brain region that GLP-1 agonists do not primarily target. The combined activation of two distinct satiety-signaling circuits is the mechanistic basis for additive efficacy.
Why cagrilintide specifically: Native amylin (human IAPP) is pharmacologically active but rapidly aggregates and is impractical as a drug. Cagrilintide incorporates multiple modifications (Aib substitutions, fatty acid conjugation for albumin binding, C-terminal amidation) that extend half-life to approximately one week — matching semaglutide's dosing interval and enabling the weekly single-injection co-formulation.
Imagine appetite as a security system with two independent alarm circuits. GLP-1 agonists like semaglutide trigger the main alarm — a loud, well-characterized signal that tells your brain "stop eating." The amylin pathway is a second, physically separate alarm in a different part of the building, wired to a different panel. CagriSema triggers both alarms at the same time. Neither circuit knows about the other — they're just both firing simultaneously. That's why the weight loss exceeds what either component alone produces: you can't muffle one alarm by silencing the other.
| Compound | GLP-1R | GIPR | AMY1/3 | GCGR | Phase 3 Weight Loss |
|---|---|---|---|---|---|
| Semaglutide | ✓ | — | — | — | ~15% (STEP 1, 68wk) |
| CagriSema | ✓ | — | ✓ | — | 22.7% (REDEFINE 1, 68wk) |
| Tirzepatide | ✓ | ✓ | — | — | ~22.5% (SURMOUNT-1, 72wk) |
| Survodutide | ✓ | — | — | ✓ | 16.6% (SYNCHRONIZE-1, 76wk) |
| Retatrutide | ✓ | ✓ | — | ✓ | ~26–28% (Phase 2/3 est.) |
Note: Cross-trial comparisons are approximate — trial designs, populations, and timepoints differ. REDEFINE 4 direct head-to-head (CagriSema 23% vs. tirzepatide 25.5%) is the most controlled comparison available.
Research Disclaimer: The following reflects published clinical and preclinical research and is not medical advice. Consult a licensed healthcare provider before making any health decisions.
CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) has been evaluated in phase IIb/III trials by Novo Nordisk (REDEFINE program), providing published human dose-escalation and efficacy data from completed RCTs.
Key References: Enebo M et al. (2021). CagriSema phase IIb REDEFINE-1. Lancet. · REDEFINE-2 NCT05394519 (2024 preliminary data). · Frias JP et al. (2020). Cagrilintide amylin receptor agonism. Lancet Diabetes Endocrinol.
CagriSema is the first major clinical validation that amylin receptor agonism adds meaningful, independent weight loss on top of GLP-1 receptor agonism. Amylin receptors (AMY1/AMY3) are structurally unrelated to GLP-1 receptors — the additive effect genuinely comes from hitting a second, independent satiety circuit.
The REDEFINE 4 direct head-to-head comparison (CagriSema 23% vs. tirzepatide 25.5%) is one of the few published head-to-head trials between next-generation obesity agents. Tirzepatide won, but CagriSema achieved competitive efficacy through a fundamentally different second-receptor mechanism — GLP-1 + amylin vs. GLP-1 + GIP.
Getting cagrilintide and semaglutide into the same vial required matching their half-lives precisely. Native amylin has a half-life of minutes — cagrilintide's Aib substitutions and C18 fatty acid conjugation extend it to ~1 week, matching semaglutide's ~1-week half-life and enabling the once-weekly fixed-dose co-formulation.
Every batch of CagriSema (cagrilintide + semaglutide) with full Certificate of Analysis documentation.